Startseite Evaluation of stability and potential interference on the α-thalassaemia early eluting peak and immunochromatographic strip test for α-thalassaemia --SEA carrier screening
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Evaluation of stability and potential interference on the α-thalassaemia early eluting peak and immunochromatographic strip test for α-thalassaemia --SEA carrier screening

  • Wing Kit Lam ORCID logo EMAIL logo , Christina Pui Ying Fan , Winnie Yim Fong Law , Tsz Fung Wong , Darcy Lok Han Too , Lok Nga Ko , Anskar Yu Hung Leung und Sze Fai Yip EMAIL logo
Veröffentlicht/Copyright: 18. August 2025
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Objectives

α-Thalassaemia screening is crucial for identifying carriers at risk of having offspring with haemoglobin (Hb) Bart’s hydrops fetalis syndrome. This study evaluated the performance of two potential screening methods: the α-thalassaemia early eluting peak (αEEP) identified by high-performance liquid chromatography (HPLC) and an immunochromatographic strip test (ICT), focusing on stability and potential interferences.

Methods

Ninety-two peripheral blood samples were used. Thirty were for assessment of αEEP and ICT stability and interference by icterus/lipaemia, and saline washing for interference removal. Diagnostic performance of αEEP and ICT were evaluated in 40 samples with glycated Hb (P2) ≥6.0 % and 22 with Hb F≥2.0 % on HPLC, using α-globin genotyping as the gold standard.

Results

Both αEEP and ICT results remained stable for 14 days. Neither test was significantly affected by icterus or lipaemia, though 3 of 20 ICT results (15 %) showed discordance after saline washing. Elevated HbA1c and Hb F altered early eluting peak patterns but did not affect αEEP interpretation. For detecting --SEA mutation, αEEP showed 100 % sensitivity and 100 % specificity when P2≥6.0 % or Hb F≥2.0 %, while ICT a low specificity (45 %) when Hb F≥2.0 %.

Conclusions

αEEP showed reliable performance in detecting α0-thalassaemia with --SEA mutation in all conditions tested, while ICT showed low specificity when Hb F≥2.0 %. These findings support αEEP as a reliable test for routine clinical laboratory use, while cautions should be made for ICT in case of elevated Hb F levels.


Corresponding authors: Dr. Wing Kit Lam and Dr. Sze Fai Yip, Department of Clinical Pathology, Tuen Mun Hospital, 23 Tsing Chung Koon Road, Tuen Mun, New Territories, Hong Kong, China, E-mail: (W. K. Lam), (S. F. Yip)

  1. Research ethics: The study was approved by the Hospital Authority Central Institutional Review Board (Ref: CIRB-2024-162-4) and performed according to the Declaration of Helsinki.

  2. Informed consent: Not applicable.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. Lam WK: conceptualisation, data curation, formal analysis, methodology, project administration, writing original draft, review and editing; Fan CPY, Law YFW, Wong TF: data curation, formal analysis, investigation; Too DLH, Ko LN: formal analysis, investigation; Leung AYH: methodology, supervision, review and editing; Yip SF: methodology, resources, supervision, review and editing.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

References

1. Amid, A, Lal, A, Coates, TD, Fucharoen, S. Guidelines for the management of α-thalassaemia, 1st ed. Nicosia, Cyprus: Thalassaemia International Federation; 2023.Suche in Google Scholar

2. Lau, YL, Chan, LC, Chan, YY, Ha, SY, Yeung, CY, Waye, JS, et al.. Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong - implications for population screening. N Engl J Med 1997;336:1298–301. https://doi.org/10.1056/nejm199705013361805.Suche in Google Scholar PubMed

3. Bain, BJ, Daniel, Y, Henthorn, J, de la Salle, B, Hogan, A, Roy, NBA, et al.. Significant haemoglobinopathies: a guideline for screening and diagnosis: a British Society for Haematology Guideline. Br J Haematol 2023;201:1047–65. https://doi.org/10.1111/bjh.18794.Suche in Google Scholar PubMed

4. Winichagoon, P, Kumpan, P, Holmes, P, Finlayson, J, Newbound, C, Kabral, A, et al.. Validation of the immunochromatographic strip for α-thalassemia screening: a multicenter study. Transl Res 2015;165:689–95. https://doi.org/10.1016/j.trsl.2014.10.013.Suche in Google Scholar PubMed

5. Lam, WK, Law, WYF, Wong, TF, Woo, VHK, Wu, AHH, Chow, EY, et al.. A specific early eluting peak in Bio-Rad Variant II cation-exchange high-performance liquid chromatography (CE-HPLC) for the screening of alpha-thalassaemia in a Chinese population. Pathology 2023;55:835–42. https://doi.org/10.1016/j.pathol.2023.05.008.Suche in Google Scholar PubMed

6. CLSI. User protocol for evaluation of qualitative test performance; approved guideline, 2nd ed. EP12-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.Suche in Google Scholar

7. CLSI. Interference testing in clinical chemistry; approved guideline, 3rd ed. EP07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.Suche in Google Scholar

8. CLSI. Supplemental tables for interference testing in clinical chemistry; approved guideline, 1st ed. EP37. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.Suche in Google Scholar

9. Chan, AY, So, CC, Ma, ES, Chan, LC. A laboratory strategy for genotyping haemoglobin H disease in the Chinese. J Clin Pathol 2007;60:931–4. https://doi.org/10.1136/jcp.2006.042242.Suche in Google Scholar PubMed PubMed Central

10. Bunkall, C, Ghallyan, N, Elliott, C, Van de Water, N, Chan, G. Evaluation of an immunochromatographic strip test for alpha-thalassaemia screening. Int J Lab Hematol 2018;40:691–6. https://doi.org/10.1111/ijlh.12905.Suche in Google Scholar PubMed

11. Pantiya, P, Chairatanapiwong, S, Dankai, D, Nualkeaw, S, Jaiping, K, Singboottra, P, et al.. False-positive result of immunochromatographic (IC) strip test for the diagnosis of α-thalassemia in samples with autoantibodies. Clin Chem Lab Med 2020;58:e44–6. https://doi.org/10.1515/cclm-2019-0827.Suche in Google Scholar PubMed

12. Tayapiwatana, C, Kuntaruk, S, Tatu, T, Chiampanichayakul, S, Munkongdee, T, Winichagoon, P, et al.. Simple method for screening of alpha-thalassaemia 1 carriers. Int J Hematol 2009;89:559–67. https://doi.org/10.1007/s12185-009-0331-4.Suche in Google Scholar PubMed

13. Chan, G, Wong, J, Sami, V. Hb Bart’s immunochromatographic test result and Hb F level in normal cord blood and in selected haemoglobinopathy cases. Int J Lab Hematol 2024;46:408–10. https://doi.org/10.1111/ijlh.14223.Suche in Google Scholar PubMed


Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/cclm-2025-0754).


Received: 2025-06-18
Accepted: 2025-08-04
Published Online: 2025-08-18
Published in Print: 2025-11-25

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Challenging the dogma: why reviewers should be allowed to use AI tools
  4. Multivariate approaches to improve the interpretation of laboratory data
  5. Review
  6. Interference of therapeutic monoclonal antibodies with electrophoresis and immunofixation of serum proteins: state of knowledge and systematic review
  7. Opinion Papers
  8. Urgent call to the European Commission to simplify and contextualize IVDR Article 5.5 for tailored and precision diagnostics
  9. The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
  10. Supplementation of pyridoxal-5′-phosphate in aminotransferase reagents: a matter of patient safety
  11. HCV serology: an unfinished agenda
  12. From metabolic profiles to clinical interpretation: multivariate approaches to population-based and personalized reference intervals and reference change values
  13. Genetics and Molecular Diagnostics
  14. A multiplex allele specific PCR capillary electrophoresis (mASPCR-CE) assay for simultaneously analysis of SMN1/SMN2/NAIP copy number and SMN1 loss-of-function variants
  15. General Clinical Chemistry and Laboratory Medicine
  16. From assessment to action: experience from a quality improvement initiative integrating indicator evaluation and adverse event analysis in a clinical laboratory
  17. Evaluation of measurement uncertainty of 11 serum proteins measured by immunoturbidimetric methods according to ISO/TS 20914: a 1-year laboratory data analysis
  18. Assessing the harmonization of current total vitamin B12 measurement methods: relevance and implications
  19. The current status of serum insulin measurements and the need for standardization
  20. Method comparison of plasma and CSF GFAP immunoassays across multiple platforms
  21. Cerebrospinal fluid leptin in Alzheimer’s disease: relationship to plasma levels and to cerebrospinal amyloid
  22. Verification of the T50 Calciprotein Crystallization test: bias estimation and interferences
  23. An innovative immunoassay for accurate aldosterone quantification: overcoming low-level inaccuracy and renal dysfunction-associated interference
  24. Oral salt loading combined with postural stimulation tests for confirming and subtyping primary aldosteronism
  25. Evaluating the performance of a multiparametric IgA assay for celiac disease diagnosis
  26. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels
  27. Reference Values and Biological Variations
  28. Establishment of region-, age- and sex-specific reference intervals for aldosterone and renin with sandwich chemiluminescence immunoassays
  29. Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
  30. Comparative analysis of population-based and personalized reference intervals for biochemical markers in peri-menopausal women: population from the PALM cohort study
  31. Hematology and Coagulation
  32. Evaluation of stability and potential interference on the α-thalassaemia early eluting peak and immunochromatographic strip test for α-thalassaemia --SEA carrier screening
  33. Cardiovascular Diseases
  34. Analytical and clinical evaluation of an automated high-sensitivity cardiac troponin I assay for whole blood
  35. Diabetes
  36. Method comparison of diabetes mellitus associated autoantibodies in serum specimens
  37. Letters to the Editor
  38. Permitting disclosed AI assistance in peer review: parity, confidentiality, and recognition
  39. Response to the editorial by Karl Lackner
  40. Hemolysis detection using the GEM 7000 at the point of care in a pediatric hospital setting: does it affect outcomes?
  41. Estimation of measurement uncertainty for free drug concentrations using ultrafiltration
  42. Cryoglobulin pre-analysis over the weekend
  43. Accelerating time from result to clinical action: impact of an automated critical results reporting system
  44. Recent decline in patient serum folate test levels using Roche Diagnostics Folate III assay
  45. Kidney stones consisting of 1-methyluric acid
  46. Congress Abstracts
  47. 7th EFLM Conference on Preanalytical Phase
  48. Association of Clinical Biochemists in Ireland Annual Conference
  49. Association of Clinical Biochemists in Ireland Annual Conference
  50. 17th Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
Heruntergeladen am 8.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-0754/html?recommended=sidebar
Button zum nach oben scrollen